Collegium Pharmaceutical Inc (COLL)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 70.92% | 64.16% | 60.36% | 56.41% | 52.28% | 50.39% | 52.01% | 57.00% | 58.87% | 65.03% | 66.29% | 67.40% | 63.97% | 56.06% | 38.39% | 26.45% | 19.88% | 23.87% | 23.69% | 24.78% |
| Operating profit margin | 36.30% | 26.69% | 21.48% | 16.08% | 8.31% | -4.00% | -6.74% | -5.39% | 6.89% | 22.12% | 24.14% | 24.83% | 20.00% | 13.56% | 3.56% | -1.97% | -4.58% | -2.01% | -3.01% | -3.53% |
| Pretax margin | 16.47% | 4.84% | -1.42% | -7.23% | -7.20% | -19.07% | -18.69% | -13.78% | -1.32% | 14.17% | 15.14% | 14.62% | 9.90% | 6.41% | 0.19% | -2.79% | -4.38% | -2.22% | -4.33% | -6.11% |
| Net profit margin | 10.47% | 2.06% | -2.59% | -6.95% | -6.24% | -13.63% | -12.59% | 16.99% | 27.95% | 34.30% | 35.68% | 14.40% | 9.52% | 6.14% | 0.05% | -2.85% | -4.38% | -2.22% | -4.33% | -6.11% |
Collegium Pharmaceutical Inc has shown consistent improvement in its profitability ratios over the quarters. The gross profit margin has steadily increased from 74.52% in Q4 2022 to 83.27% in Q4 2023, indicating efficient cost management and strong pricing power.
The operating profit margin has shown significant improvement, rising from 7.18% in Q4 2022 to 29.46% in Q4 2023. This indicates better operational efficiency and cost control measures implemented by the company.
Similarly, the pretax margin has improved from -6.22% in Q4 2022 to 13.36% in Q4 2023, reflecting enhanced profitability before accounting for taxes.
The net profit margin has also shown a positive trend, increasing from -11.84% in Q3 2022 to 8.50% in Q4 2023. This improvement suggests that the company is effectively managing its expenses and generating higher net income relative to its revenue.
Overall, Collegium Pharmaceutical Inc's profitability ratios have demonstrated a positive trajectory, reflecting improved efficiency, cost management, and overall financial performance.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 14.60% | 9.94% | 7.62% | 5.60% | 2.84% | -1.05% | -1.52% | -1.09% | 2.55% | 9.00% | 10.12% | 11.20% | 8.73% | 6.04% | 1.99% | -1.37% | -7.75% | -3.41% | -5.04% | -5.93% |
| Return on assets (ROA) | 4.21% | 0.77% | -0.92% | -2.42% | -2.13% | -3.57% | -2.83% | 3.43% | 10.33% | 13.95% | 14.96% | 6.50% | 4.16% | 2.73% | 0.03% | -1.98% | -7.42% | -3.76% | -7.24% | -10.25% |
| Return on total capital | 23.42% | 14.98% | 9.94% | 6.07% | 4.69% | -1.61% | -2.29% | -1.57% | 4.36% | 14.37% | 15.10% | 17.77% | 14.33% | 10.12% | 3.68% | -1.93% | -24.05% | -10.64% | -15.92% | -18.32% |
| Return on equity (ROE) | 24.64% | 5.04% | -5.56% | -16.33% | -12.83% | -21.72% | -17.84% | 21.82% | 35.24% | 41.22% | 42.18% | 24.68% | 14.38% | 10.19% | 0.13% | -8.91% | -25.99% | -13.57% | -25.43% | -34.95% |
Collegium Pharmaceutical Inc's profitability ratios show a fluctuating trend over the past eight quarters.
- Operating return on assets (Operating ROA) has improved significantly from 2.84% in Q4 2022 to 14.60% in Q4 2023, indicating that the company is generating more income from its assets through operations.
- Return on assets (ROA) shows a volatile pattern with negative values in several quarters, suggesting the company's profitability relative to its total assets has been inconsistent.
- Return on total capital has also shown an upward trend, reaching 19.36% in Q4 2023, indicating that the company is efficiently utilizing its total capital to generate returns for its stakeholders.
- Return on equity (ROE) has improved notably from -21.72% in Q3 2022 to 24.64% in Q4 2023, demonstrating that the company is becoming more profitable for its equity investors.
Overall, Collegium Pharmaceutical Inc's profitability ratios reflect improvements in operational efficiency and capital utilization, with ROE showing a particularly strong performance in the most recent quarter. Regular monitoring of these ratios will be essential to assess the company's financial health and performance in the future.